PEG conjugated VEGF siRNA for anti-angiogenic gene therapy.

A novel siRNA delivery system based on polyelectrolyte complex (PEC) micelles was introduced in this study. Vascular endothelial growth factor (VEGF) siRNA was conjugated to poly(ethylene glycol) (PEG) via a disulfide linkage (siRNA-PEG). The siRNA-PEG conjugate could form PEC micelles by interacting with cationic polyethylenimine (PEI) as a core forming agent. The VEGF siRNA-PEG/PEI PEC micelles showed greater stability than naked VEGF siRNA against enzymatic degradation. Under a reductive condition similar to cytosolic environment, an intact form of siRNA was released from the siRNA-PEG conjugate by cleavage of the disulfide linkage. The VEGF siRNA-PEG/PEI PEC micelles effectively silenced VEGF gene expression in prostate carcinoma cells (PC-3) up to 96.5% under an optimized formulation condition. They also showed a far superior VEGF gene silencing effect than VEGF siRNA/PEI complexes even in the presence of serum. This study suggests that the siRNA delivery system using VEGF siRNA-PEG/PEI PEC micelles could be potentially applied to RNAi-based anti-angiogenic treatment of cancer in vivo.

[1]  T. Park,et al.  A new antisense oligonucleotide delivery system based on self-assembled ODN-PEG hybrid conjugate micelles. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[2]  P. Scambler,et al.  A rapid and sensitive assay for quantification of siRNA efficiency and specificity , 2005, Biological Procedures Online.

[3]  A. Hamilton,et al.  RNA–DNA Interactions and DNA Methylation in Post-Transcriptional Gene Silencing , 1999, Plant Cell.

[4]  J. Kopeček,et al.  PEGylation of poly(ethylene imine) affects stability of complexes with plasmid DNA under in vivo conditions in a dose-dependent manner after intravenous injection into mice. , 2005, Bioconjugate chemistry.

[5]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Park,et al.  Stabilization of recombinant interferon-α by pegylation for encapsulation in PLGA microspheres , 2003 .

[7]  P. Chaudhary,et al.  Use of adeno-associated viral vector for delivery of small interfering RNA , 2003, Oncogene.

[8]  R. Griffey,et al.  Positional effect of chemical modifications on short interference RNA activity in mammalian cells. , 2005, Journal of medicinal chemistry.

[9]  K. Kataoka,et al.  Smart Polyion Complex Micelles for Targeted Intracellular Delivery of PEGylated Antisense Oligonucleotides Containing Acid‐Labile Linkages , 2005, Chembiochem : a European journal of chemical biology.

[10]  R. Schiffelers,et al.  Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. , 2004, Nucleic acids research.

[11]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[12]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[13]  Y. Barenholz,et al.  Oligonucleotide lipoplexes: the influence of oligonucleotide composition on complexation. , 2001, Biochimica et biophysica acta.

[14]  Richard J. H. Smith,et al.  In vitro and in vivo suppression of GJB2 expression by RNA interference. , 2005, Human molecular genetics.

[15]  Y. Youn,et al.  Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics. , 2006, International journal of pharmaceutics.

[16]  P. Sharp,et al.  RNAi Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals , 2000, Cell.

[17]  David R Corey,et al.  RNA interference in mammalian cells by chemically-modified RNA. , 2003, Biochemistry.

[18]  A. Caudy,et al.  Role for a bidentate ribonuclease in the initiation step of RNA interference , 2001 .

[19]  L. Ellis,et al.  The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.

[20]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[21]  F. Vergeldt,et al.  Aquaporins of the PIP2 Class Are Required for Efficient Anther Dehiscence in Tobacco , 2005, Plant Physiology.

[22]  S. W. Kim,et al.  A new synthesis of galactose-poly(ethylene glycol)-polyethylenimine for gene delivery to hepatocytes. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Jung-Ki Park,et al.  Effect of polyethylene glycol on gene delivery of polyethylenimine. , 2003, Biological & pharmaceutical bulletin.

[24]  S. Sacks,et al.  RNA interference – a new experimental and therapeutic tool , 2005, Current opinion in nephrology and hypertension.

[25]  J. Tao,et al.  Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach , 2005, The British journal of dermatology.

[26]  Kazunori Kataoka,et al.  Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. , 2005, Journal of the American Chemical Society.

[27]  N. Ballatori,et al.  Endogenous glutathione conjugates: occurrence and biological functions. , 1998, Pharmacological reviews.

[28]  A. Gartel,et al.  RNA interference in cancer. , 2006, Biomolecular engineering.

[29]  T. Park,et al.  Polyelectrolyte complex micelles composed of c-raf antisense oligodeoxynucleotide-poly(ethylene glycol) conjugate and poly(ethylenimine): effect of systemic administration on tumor growth. , 2005, Bioconjugate chemistry.

[30]  A. Aigner,et al.  RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo , 2005, Gene Therapy.

[31]  A. Reynolds,et al.  Rational siRNA design for RNA interference , 2004, Nature Biotechnology.

[32]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[33]  P. Kruk,et al.  The genesis of RNA interference, its potential clinical applications, and implications in gynecologic cancer. , 2005, Gynecologic oncology.

[34]  M. Amarzguioui,et al.  Tolerance for mutations and chemical modifications in a siRNA. , 2003, Nucleic acids research.

[35]  T. Park,et al.  In vivo tumor targeting of ODN-PEG-folic acid/PEI polyelectrolyte complex micelles , 2005, Journal of biomaterials science. Polymer edition.

[36]  D. Carbone,et al.  Erratum: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells (Nature Medicine 2, 1096-1103 (1996)) , 1996 .

[37]  Y. Yuzawa,et al.  A Small Interfering RNA Targeting Vascular Endothelial Growth Factor as Cancer Therapeutics , 2004, Cancer Research.

[38]  Alan M Gewirtz,et al.  Progress in the Development of Nucleic Acids Therapeutics for Cancer , 2004, Cancer biology & therapy.